晨间信号Morning Signal
《科学新闻》 2026年11月刊 · 中文解读

CAR-T细胞疗法为僵人综合征患者带来新未来

A New Future · Meghan Rosen
约 28 分钟Features在小程序里点播,20 到 60 分钟做好
这篇讲什么
美国首位接受CAR-T细胞疗法治疗僵人综合征的患者Lynn Montgomery-Haga,在治疗前连走完走廊都困难,如今已能重新行走、园艺和做家务。这种疗法通过改造患者自身的T细胞来清除产生致病抗体的B细胞,若获美国食品药品监督管理局批准,将成为首个获批治疗自身免疫病的CAR-T疗法。研究人员希望它还能用于狼疮、类风湿关节炎和多发性硬化等疾病,但其长期安全性和疗效持续时间仍待观察。
原文开头
Lynn Montgomery-Haga is the first person in the United States to be treated with CAR T cell therapy for stiff person syndrome. Two months before the treatment that would change Lynn Montgomery-Haga’s life, she could barely walk down a hallway. In a test at the University of Colorado Anschutz, Montgomery-Haga struggled to walk 25 feet, often reaching out to the walls for support. Usually, the 49-year-old relied on her walker or wheelchair. “She had a very stiff, hesitant gait,” says Montgomery-Haga’s neurologist, Amanda Piquet. For about a decade, Montgomery-Haga had lived with a debilitating autoimmune disease known as stiff person syndrome. …
摘自《科学新闻》(Science News)2026年11月刊,Meghan Rosen。仅引用开头一小段供了解文章,版权归原刊所有,全文请阅读原刊。
晨间信号小程序码
微信扫码,在小程序里听完整版
不用登录先听一篇 · 或在微信搜索小程序 晨间信号
同期其他文章